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Attention-Deficit Hyperactive Disorder (ADHD) is one of the most common mental
health disorders amongst school-aged children with an estimated prevalence of 5% in
the global population (American Psychiatric Association, 2013). Stimulants, particularly
methylphenidate (MPH), are the first-line option in the treatment of ADHD (Reeves and
Schweitzer, 2004; Dopheide and Pliszka, 2009) and are prescribed to an increasing
number of children and adolescents in the US and the UK every year (Safer et al.,
1996; McCarthy et al., 2009), though recent studies suggest that this is tailing off, e.g.,
Holden et al. (2013). Around 70% of children demonstrate a clinically significant treatment
response to stimulant medication (Spencer et al., 1996; Schachter et al., 2001; Swanson
et al., 2001; Barbaresi et al., 2006). However, it is unclear which patient characteristics
may moderate treatment effectiveness. As such, most existing research has focused on
investigating univariate or multivariate correlations between a set of patient characteristics
and the treatment outcome, with respect to dosage of one or several types of
medication. The results of such studies are often contradictory and inconclusive due to
a combination of small sample sizes, low-quality data, or a lack of available information
on covariates. In this paper, feature extraction techniques such as latent trait analysis
were applied to reduce the dimension of on a large dataset of patient characteristics,
including the responses to symptom-based questionnaires, developmental health
factors, demographic variables such as age and gender, and socioeconomic factors
such as parental income. We introduce a Bayesian modeling approach in a “learning in
themodel space” framework that combines existing knowledge in the literature on factors
that may potentially affect treatment response, with constraints imposed by a treatment
response model. The model is personalized such that the variability among subjects
is accounted for by a set of subject-specific parameters. For remission classification,
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this approach compares favorably with conventional methods such as support vector
machines and mixed effect models on a range of performance measures. For instance,
the proposed approach achieved an area under receiver operator characteristic curve
of 82–84%, compared to 75–77% obtained from conventional regression or machine
learning (“learning in the data space”) methods.
Keywords: attention-deficit hyperactivity disorder, Bayesian inference, machine learning, methylphenidate, mixed
effects model, personalized medicine, prognosis, treatment response
1. INTRODUCTION
The ability to predict treatment response (or non-response) in
patients with mental health issues is potentially beneficial to
both clinicians and patients in a number of ways. First, any
treatment is accompanied by the risk of adverse effects—where
non-response is a probable outcome then the risks of treatment
may outweigh the benefits. Second, prediction of treatment
response may guide both the dose and choice of medication.
For example, where adverse events are dose-dependent then a
clinician may chose to abandon a treatment course if a patient
was a probable non-responder. Third, response prediction
helps to calibrate both clinician and patient expectations of
treatment outcomes. Finally, identifying non-responders may
prompt a re-appraisal of the diagnosis and formulation of
a patient’s problem—misdiagnosis being one potential cause
of non-response. These benefits certainly apply to Attention-
Deficit Hyperactive Disorder (ADHD), which is one of the most
common developmental disorders among school-aged children
with an estimated prevalence of 5% in the general population
worldwide (American Psychiatric Association, 2013). Stimulants,
particularly methylphenidate (MPH), are the first-line option in
the treatment of ADHD (Reeves and Schweitzer, 2004; Dopheide
and Pliszka, 2009). Stimulants are prescribed to an increasing
number of children and adolescents in the US and the UK every
year (Safer et al., 1996; McCarthy et al., 2009), though recent
studies suggest that this trend is tailing off e.g., Holden et al.
(2013). The beneficial effects of stimulant medication on the
core symptoms of ADHD have been demonstrated by numerous
clinical trials, reviews and meta-analyses (Banaschewski et al.,
2006; Greenhill et al., 2006; van der Oord et al., 2008; Storebø
et al., 2015). Nevertheless, adverse effects of the medications are
also common (Storebø et al., 2015). The findings from previous
research suggest that around 70% of children demonstrate a
clinically significant treatment response to stimulant medication
(Spencer et al., 1996; Schachter et al., 2001; Swanson et al.,
2001; Barbaresi et al., 2006). However, it is unclear which
patient characteristics may moderate treatment effectiveness and
whether non-response can be predicted.
To date, achieving accurate predictions of the clinical
outcomes for patients with ADHD has proven elusive—most
of the literature has focused on investigating the potential
correlations between a set of patient characteristics and the
outcome following treatment with one or more types of
medication. Information relating to patient characteristics has
mostly been in the form of subjective questionnaire ratings,
clinical notes and qualitative psychometric data; for example,
the ratings from symptom-based questionnaires such as the
Swanson, Nolan, and Pelham (SNAP) questionnaire (Swanson
et al., 1983; Atkins et al., 1985; Swanson, 1992; Bussing et al.,
2008), along with demographic variables such as age, sex and
social economic background. The results from such studies are
often contradictory and inconclusive due to small sample sizes
and/or limited availability and quality of data, especially in the
temporal (longitudinal) domain.
Along withmore conventional statistical approaches, machine
learning has also shown promise in predicting treatment
response or prognosis in healthcare applications. Indeed, recently
a random forest regression analysis was used to predict outcome
in a group of patients affected by Obsessive Compulsive Disorder
(OCD) from a relatively small pool of questionnaire items, with
a reported error rate of 24.6% (Askland et al., 2015). Likewise,
there has been a previous attempt to use machine learning
techniques to predict treatment response in ADHD (Kim et al.,
2015); support vector machine classification from this study was
reported as 84.6% accurate (not to be confused with the balanced
accuracy measure used in this paper). However, in addition to
demographic and clinical questionnaire-derived data, the study
used genetic as well as neuroimaging and neuropsychological
information as inputs. Such data are unlikely to be readily
available to clinicians in routine practice.
In this paper we investigate whether the inclusion of prior
knowledge relating to the potential mechanism behind the
presentation of a mental health condition and characteristics of
individual patients can add value in predicting treatment. Thus,
we hypothesized that a pragmatic machine learning approach
based on a mechanistic or parametric model (a “learning in
the model space” framework) for treatment response prediction
may offer an advantage over more conventional methods
(Brodersen et al., 2011; Doyle et al., 2013; Chen et al., 2014;
Shen et al., 2016). This method represents each newly observed
patient through a model; the models are personalized such that
individual differences are accounted for by a set of subject-
specific parameters. In the case of ADHD, developing a plausible
mechanistic model is not straightforward—despite decades of
research, the underlying mechanism for the disorder is not well
understood. In addition, anymechanistic model would have to be
based on data that are likely to be available in good, but routine,
clinical practice.
This paper documents, within the “learning in the model
space” framework, a Bayesian linear regression model for
the prediction of treatment response in a cohort of children
diagnosed and treated for ADHD in the UK. The performance of
this new approach is then comparedwith conventional regression
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and machine learning methods (“learning in the data space”) to
assess whether or not the new approach offers benefits, and if so
under what circumstances.
2. MATERIALS AND METHODS
2.1. Participants
The children enrolled in the study were drawn from the
ADHD Drug Use and Chronic Effects (ADDUCE) cohort study
(The ADDUCE Consortium, 2016), covered by a data sharing
agreement with patient consent. The participants were from the
UK NHS Tayside region who had attended the ADHD treatment
clinics held at Dundee and Perth, UK. 262 families of eligible
children were contacted, of which 181 (70%) were recruited
and data on 173 of them were obtained for the purpose of this
study. In addition, data were available on 94 healthy controls.
Out of the 173 patients (whose baseline data are available),
157 of them started dose optimization studies and therefore
longitudinal (temporal) data are available (See Section 3.1). To
be eligible for the ADHD group, children had to be 6–17 years
of age, have a clinical diagnosis of ADHD (see below), have had
no previousmedical history of methylphenidate use (medication-
naïve) and have parental and child consent/assent to commence.
The criteria for the healthy control group were similar apart
from them having no current or previous psychiatric diagnoses.
The recruitment was carried out over a 30-month period from
January 2012–August 2014.
All patients in the ADHD group had already been clinically
diagnosed with ADHD; this diagnosis was based on the
clinical judgment of the assessing physician, informed by
structured interviews with parents/carers, information provided
by the child’s school, direct observation of the child at the
clinic, and at times, in their educational setting. Thus, the
physician had to be satisfied that the child fulfilled the
diagnostic criteria for a hyperkinetic disorder according to the
International Classification of Diseases 10th edition (ICD-10)
(World Health Organization, 2010), or ADHD as defined by
the Diagnostic and Statistical Manual 4th edition (DSM-IV)
(American Psychiatric Association, 2000). This means that the
child had to demonstrate disabling and pervasive inattentiveness,
hyperactivity, and impulsivity across a range of settings. The
clinic was designed to implement a “dose optimization titration”
scheme of medication in children diagnosed with ADHD. This
involved giving increasing doses of methylphenidate (as the first
line medication) at roughly weekly intervals until remission from
symptoms was achieved or problematic adverse effects were
encountered. If remission was not achieved with a first line
medication within recommended dosage limits, or if problematic
side-effects were encountered then a second line drug was
initiated, and again, increased in dosage, as before.
2.2. Assessment
A range of baseline social and demographic factors was recorded,
including parental marital status, family composition, and
socioeconomic status as indicated by the Scottish Index of
Multiple Deprivation (SIMD) 2012 (APS Group Scotland, 2012)
derived from the family home postcode. A history of any
previous psychiatric or non-psychiatric medication exposure
was recorded, as were any physical health issues. Verbal and
non-verbal intellectual functioning was estimated from parental
reports and any educational issues noted. Problems with anxiety
and low mood were rated using the short form of the Mood
and Feelings Questionnaire (MFQ) with the parents, and where
appropriate, the child as informants (Angold et al., 1996).
Dystonia and abnormal movements were recorded using the
Abnormal Involuntary Movement Scale (AIMS) (Guy, 1974, pp.
534–537). Oppositional and ADHD symptoms and behaviors
were rated, according to parental report, using the Swanson,
Nolan, and Pelham (SNAP-IV) questionnaire (Swanson et al.,
1983). Any substance used by the participants was recorded
using the Substance Use Questionnaire (SUQ). Fine motor
issues were recorded using the Developmental Coordination
Disorder Questionnaire 2007 (DCDQ’07). Several sections of
the Development and Well-Being Assessment (DAWBA) were
used (Goodman et al., 2000); these were (1) Rapidly Changing
Mood (child and parent versions), (2) Tic disorders, including the
Tourette syndrome, (3) Awkward and troublesome behavior. Tic
severity (where present) was also rated using the Yale Global Tic
Severity Scale (YGTSS) (Leckman et al., 1989). Possible behaviors
associated with an underlying Autism Spectrum Disorder (ASD)
were evaluated using the Social Communication Questionnaire
(SCQ) (Rutter et al., 2003). The Strengths and Difficulties
Questionnaire (SDQ) (Goodman, 1997-07) was used to rate
parental perceived levels of pro-social behavior, hyperactivity/
impulsivity, conduct problems, emotional symptoms and peer
relationship problems. The overall clinical impression was
recorded using the Clinical Global Impression—Severity scale
(CGI-S) (Guy, 1974, pp. 218–222) and Children’s Global
Assessment Scale (CGAS) (Shaffer et al., 1983).
Responses to medication, in terms of levels of ADHD
symptoms, were reported by parents and recorded using
the SNAP-IV questionnaire at each visit. Likewise, any
potential adverse effects and co-morbidity problems were
reported using the standard clinic proforma, along with
weight, height and blood pressure of the child at each
visit.
2.3. Feature Extraction/Factor Analysis
The aforementioned questionnaires included a large number
of items with categorical (binary or ordinal) response formats.
Thus, in order to facilitate model development by reducing
the dimensionality of the data whilst minimizing the loss
of information, a series of factor (latent trait) analyses were
conducted.
The key questionnaires used in the modeling process were
the SCQ, the SDQ, and the SNAP-IV (see the previous section).
In particular, the SNAP-IV scores served as the outcome
variables, which indicated whether symptomatic remission
had been achieved, following the dose-optimized titration
of medication. The factor analyses sought to identify the
dimensionality underlying the responses to the questionnaires
and, consequently, the standardized factor scores represented the
level of trait for each patient in that underlying dimension or
construct.
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In order to estimate the dimensionality, the sample of 173
patients and 94 healthy controls was randomly divided into
two roughly equal exploratory and confirmatory datasets. A
parallel analysis (Horn, 1965), adapted for categorical data,
was then implemented in the freeware FACTOR (Lorenzo-
Seva and Ferrando, 2006) using unweighted least squares (ULS)
estimation method. A weighted “promax” rotation was deployed
to achieve factor simplicity (Abdi, 2003). The maximum number
of plausible factors (latent variables) was assumed to be indicated
at the point where the eigenvalues of the factors in randomly
generated data exceeded those observed in the real data. A series
of exploratory factor analyses (EFAs–adapted for categorical
dependent variables) were then conducted to aid interpretation
of the factors. Oblique “geomin” rotation was used (Asparouhov
and Muthén, 2009), assuming that, as in almost all psychological
measures, underlying latent traits would be correlated with each
other to some extent (Thurstone, 1931). A series of confirmatory
factor analyses (CFAs) were then conducted using the held-
back, confirmatory data (see Section 3.1 on cross-validation),
in order to ensure that the factor structures derived fitted
the data adequately. All EFAs and CFAs were conducted in
the Mplus software version 7.1, using robust weighted least
squares with mean and variance adjustment (WLSMV) as the
estimation method (Muthén et al., 1997). Remission was defined
by a child having a reported factor score in the hyperactive
and inattentive dimensions (both elicited from factor analysis)
equivalent to a mean item score in the SNAP-IV of one or less,
which is conventionally taken to indicate symptomatic remission
(Hechtman, 2005; Chou et al., 2012). The resulting symptom
score thresholds are only slightly different for inattentiveness and
hyperactivity (−0.97 vs.−0.92).
3. MODELING APPROACH
The causal factor model, shown in Figure 1, was derived using
a rapid review approach to appraise and synthesize the existing
evidence (Khangura et al., 2012). This model also took into
account the nature of the data available in the cohort and was
modified accordingly. The goal is not for the causal model to be
comprehensive or definitive, but to identify from the literature
FIGURE 1 | High level causal factor model of treatment response prediction in ADHD.
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as many potential factors relating to treatment response as there
are available from the dataset, as well as helping to elicit the
Bayesian prior distributions (Section 3.2.1). Model development
was based on a literature review. This involved running searches
in the EMBASE, MEDLINE and PsycINFO databases using
the synonyms for ADHD (e.g., hyperkinesis) combined with
terms relating to treatment outcome or response, and the names
of the medications (both scientific and trademarks, full and
abbreviated) prescribed in the cohort. The medications include
1) immediate release methylphenidate (IR-MPH, e.g., Ritalin R©),
2) long-acting methylphenidate (XR-MPH, e.g., Concerta XL R©,
Equasym XL R©, Medikinet XL R©), 3) dextroamphetamine (DEX,
e.g., Dexedrine R©) including its prodrug lisdexamfetamine
dimesylate (e.g., Elvanse R©), and 4) atomoxetine (ATOM, e.g.,
Strattera R©). Secondary sources were followed up. The quality
of trial-based studies could be appraised using the CONSORT
checklist (Schulz et al., 2010) and observational studies via the
STROBE guidance (von Elm et al., 2007). Two of the authors
(HKW and PAT) then made a judgment, based on the findings
reported in the literature and the perceived likelihood of bias
or uncertainty as to what extent variables in the model might
be related to treatment response in ADHD. The model derived
was consequently used to populate prior distributions for the
patient-specific model parameters (i.e., the hyperpriors). Where
the evidence was uncertain or inconsistent, the variances (i.e.,
imprecision) of the hyperpriors were increased.
Not every piece of information mentioned in Section 2.2
was used for the purpose of modeling, because of insufficient
data or multicollinearity between the variables. The causal
factor model was then simplified based on the breadth of
available data from the cohort, leading to a much reduced model
as shown in Figure 2. Some factors were combined through
another layer of feature extraction; for example, the motor and
control latent factors, themselves also obtained from applying
feature extraction to the DCDQ’07 questionnaire data (see
Section 2.2), were combined with the non-verbal communication
factor from the SCQ questionnaire to obtain a developmental
adversity factor. Some factors were not obtained from standard
questionnaires; for example, the perinatal adversity factor (see
Figure 2) was constructed from birth weight and gestation
age; the family size and socioeconomic status factor combined
the number of siblings, parental house ownership (owned,
mortgaged or rented) and the SIMD 2012 index (APS Group
Scotland, 2012).
3.1. Data
There were 267 subjects whose baseline characteristics were
measured (173 clinically diagnosed with ADHD and 94 healthy
controls) at the first clinical appointment. Of the 173 non-
controls, 157 were enrolled in dose optimization titration
studies with parental consent, for whom longitudinal (temporal)
data are available. The 157 patients with longitudinal data
were randomized and 10-fold cross-validation partitions were
constructed. Subjects were partitioned into 10 subgroups of
roughly equal size in a patient-coherent fashion, i.e., data from
a single patient only appeared in a single fold.
FIGURE 2 | Reduced causal factor model of treatment response prediction in ADHD.
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For all models investigated in this paper, a single fold was
used as the validation dataset and the remaining nine folds were
combined to serve as the training dataset. This process was
iterated until each fold had served as validation data exactly
once.
3.1.1. Baseline Characteristics
We labeled the patient subjects by the indexing variable s =
1, 2, . . . ,N. A set of L patient-specific baseline continuous
latent factors, encoded in a row vector bs ∈ R1×L was
obtained by performing feature extraction as described in
Section 2.3 over the questionnaires detailed in Section 2.2.
Referring to Figure 2, L = 14 factors were used for
the baseline. Data from the controls in addition to the
training dataset were utilized during feature extraction to
ensure that the resulting latent factor models can sufficiently
encompass the entire range of characteristics from ADHD
patients to normal children. The resulting continuous latent
factors would, in theory, be sufficiently representative of the
information conveyed by the categorical questionnaire response
variables.
To ensure that validation data were strictly not used for the
model building, feature extraction was first performed using only
training data from each of the folds (plus all the controls). This
resulted in 10 sets of factor scores corresponding to each fold.
The factor model structures (e.g., the number of factors per
questionnaire) over the folds did not change across the folds,
as statistical fit indices and Chi-square difference tests did not
suggest that any changes were necessary. The factor models were
then used to estimate the baseline factor scores for the validation
sets in each of the folds.
Each of the 10 cross-validation runs resulted in a set of
corresponding continuous latent factors, which were used as
inputs to subsequent models. The models were trained and
validated using the same training-validation partitioning used in
the feature extraction process.
3.1.2. Longitudinal Data
Each of the 157 subjects with longitudinal data visited the
clinic a varying number of times—from titration, stabilization
to continuing care; the number of doctor’s appointments, As,
varies from 1 to 22. At each appointment, the parent or
guardian of the patient was asked to fill in an 18-item SNAP-IV
questionnaire, which measures the degree of inattentiveness and
hyperactivity. The responses were entered into a factor model
(identified through feature extraction) to extract a continuous
symptom score for inattentiveness and hyperactivity. We denote
the appointment number by the indexing variable a so that
a = 1, 2, . . . ,As. Let the independent “input” variables ma,1,
ma,2,ma,3,ma,4 be the four types of medications, respectively, IR-
MPH, XR-MPH, DEX, and ATOM for subject s at appointment a.
Using datasheets for the medicines used, the dosages of DEX and
ATOM were normalized to an equivalent daily dosage (EDD) of
IR-MPH. For all a and s, this results in input and output matrices
of the form:
Input:Ms =


m1,1 m1,2 m1,3 m1,4
m2,1 m2,2 m2,3 m2,4
...
...
...
...
ma,1 ma,2 ma,3 ma,4
...
...
...
...
mAs,1 mAs,2 mAs,3 mAs,4


(1)
Output: ys =
[
r1 r2 r3 . . . rAs
]⊺
, (2)
where r is the symptom severity measure and can be either the
inattentiveness factor score or the hyperactivity factor score.
The combined EDDs of medications (for the 4 types)
prescribed over the appointment number for all patients are
plotted as a boxplot in Figure 3. One can observe that as forced
titration progressed over the appointments, the overall dosage
level increased.
FIGURE 3 | Boxplot of combined equivalent (in IR-MPHunits) daily dosages of medications taken for all patients vs. appointment number. Red
horizontal lines: median; boxes: interquartile range; whiskers: 95% confidence intervals; red crosses: outliers.
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Figure 4 shows the distribution of inattentiveness and
hyperactivity symptom factor scores for the patients for each
appointment. The lower the factor scores, the less severe
the symptoms are. In terms of a general trend, one can
clearly see an effective and quick reduction in symptom
levels over the first 5 appointments, as stimulant medication
prescription ramps up during forced titration. The symptom
scores cease to improve for appointments 6–8, after which a
slight increase can be observed. This hints at adherence or
persistence issues, but the available data do not allow further
investigation—as such issues are not consistently reported by
the parent/guardian or recorded in the clinical notes. While
the model has no mechanism for modeling such effects,
the adaptive learning nature of the Bayesian algorithm is
able to self-correct and compensate for small deviations, for
example, by “learning” to weight down the dose-response
parameter for a given medication when the patient has a low
adherence.
3.2. Treatment Response Model
Formulation
The treatment outcome is modeled as a linear combination of the
baseline variables and the medication dosage,
ys = Xsωs + ǫ (3)
where
Xs =


bs 1
... Ms
...
bs 1

 , (4)
ǫ ∼ N
(
0, σǫ , s
2
)
∈ RAs×1 is an error term and ωs ∈ RP×1 is
the subject-specific parameter vector moderating the effect of the
baseline variables bs on the treatment response, i.e., it accounts
for how large an effect each of the various baseline variables or
medication types has on treatment outcome. “Subject-specific”
means that the parameter vector was allowed to be different for
each subject so that patients with similar baseline characteristics
can still have a different prediction outcome. The number of free
parameters required is P = L + 4 + 1 = 19 for L = 14 (see
Figure 2).
The baseline variables remain unchanged over different
appointments while the medication dosage may vary
according to the titration regime specified by the
clinician. Hence, every row of the matrix Xs contains
the same baseline characteristic vector for an individual
patient, combined with the medication dosage vector.
The row number in Xs corresponds to the appointment
number.
Because the number of visits As of the subjects was usually
fewer than the dimension of the parameter space P, the
problem is mathematically underdetermined. Hence, classical
least squares regression methods would fail without an
appropriate regularization (Goodfellow et al., 2016). To
this end, we employ a Bayesian formulation. In particular,
the Bayesian linear regression was used to model the
temporal evolution of the dose-response relationship for each
patient.
In essence, a Bayesian approach allows prior or expert
knowledge to be encoded into the problem formulation and this
enables a probabilistic solution to be found despite the limited
data available.
3.2.1. Prior Distributions and Knowledge
The joint prior probability density function Pr
(
ω, σ 2
)
is given
in Equation (A3, Supplementary Material). In this exercise,
the causal treatment response model based on the literature
was used to constrain the prior of ω and its covariance
matrix3−10 .
FIGURE 4 | Boxplots of symptom scores across all patients vs. appointment number. (A) Inattentiveness, (B) hyperactivity. Red horizontal lines: median;
boxes: interquartile range; whiskers: 95% confidence intervals; red crosses: outliers.
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When eliciting the prior, quantitative information from
the literature was not used, e.g., setting the mean of the
prior distribution of the parameter vector omega to a specific
numerical value. This is because the demography, sample sizes
and effect sizes across literature vary and there is no correct
way to normalize them. Instead, only the sign (direction) of
the effect was encoded. For example, there is evidence that
methylphenidate improves treatment response in the literature
(a positive dose results in lower symptom score), therefore
a negative value of −1 was specified for the columns of τ 0
corresponding to ma,1 . . .ma,4 in Equation (1). For positive
associations with symptom scores, +1 was used instead. The
same magnitude is used in other factors (i.e., either+1 or−1).
Each cohort study or clinical trial from the rapid review was
appraised, respectively, using the STROBE and the CONSORT
checklists by counting the number of pass and fail items out
of the total. Evidence from the literature was marked as good
quality when both the checklist score was similar to other studies
on the same topic (within 20% from the best) and effect sizes
were statistically significant as reported by the authors for the
sample size used. The diagonals of the covariance matrix 3−10
were assigned an initial value of one; for every contradicting
evidence (the effect sizes are opposite in direction) satisfying
these criteria, 0.5 was added to the corresponding variance
in the covariance matrix. A higher value may be specified if
necessary, to ensure that the prior distribution of parameter
omega spans both positive and negative sides sufficiently—within
one standard deviation of τ 0. On the other hand, if the effect sizes
are positive the variance was reduced by 0.1 for each supporting
studies, at the same time ensuring the variance does not go below
0.5. The (lack of) proposed existence of causal links between the
variables in the causal model (see Figure 1) ensures the sparsity
of the covariance matrix3−10 .
While these numbers may not be completely objective, the
amount of data available means that the sensitivity of the results
to the prior is low—sensitivity analysis shows that the effect of
scaling the prior covariance between 50 and 150% of its original
values changes the errors by about 5% of the training root mean
squared (rms) error, and 3% for the validation rms error.
3.2.2. Posterior Distributions
The posterior distribution is given in Equation (A4,
Supplementary Material), where the parameters of the
distributions are obtained through Equation (A5) in
Supplementary Material. In the training set, Bayesian learning
uses data from all of the appointments that a subject had, in
which case n = As where, as before, As is the total number of
visits or appointments a subject has and data are available for.
We introduce the simplified notations after Bayesian update
has been applied to the training set using Equation (A5) in
Supplementary Material, so that
3−1As → 3ˆ
−1
s , τAs → τˆ s, αAs → αˆs and βAs → βˆs. (5)
This notation will be used in later sections. The reader should
be reminded that the parameters are derived from each subject
and hence are different across subjects. Notice that in a prediction
exercise (instead of retrospective regression formulated here), the
learning can be applied incrementally for each future observation
with each update using just the new observation.
3.3. Virtual Patient Profile
When a new patient (denoted by s = ∗) is received, one
can measure their baseline variables b∗, but not their model
parameter space ω∗. The goal is to estimate a virtual patient
profile that is believed to best describe the new patient using
only the available baseline measurements. To do this one
derives the mathematical mapping functions from the baseline
characteristics of a patient to their posterior parameters b∗ 7→
Pr (ω∗) and Pr
(
σ 2∗
)
, such that a prediction can be made from
the baseline variables. These functions are forged using machine
learning on the existing pool of training data. Since Pr (ωs) is
parameterized by
(
τ s,3
−1
s
)
and likewise Pr
(
σ 2s
)
by
(
αs,βs
)
,
one has to learn the mappings from the baseline variables to
the parameters. The learnt mathematical mapping functions can
then be used to obtain estimates of (τˆ ∗, 3ˆ
−1
∗ ) and (αˆ∗, βˆ∗), which
represent the virtual patent profile for the new patient in the
model space.
Due to the conjugate nature of the priors, one does
not need to derive the hyperparameters αˆ∗ and βˆ∗ from
Equation (5) for the purpose of having point estimates for the
treatment response prediction. However, these hyperparameters
are necessary in order to derive the posterior distribution of
the predicted value—commonly referred to as the posterior
predictive distribution. Knowing the distribution allows us
to approximate the uncertainties of the estimates, e.g., 95%
confidence intervals. Two methods were proposed for learning
the mappings from the baseline variables to the virtual patient
profile and they are introduced in the following subsections.
3.3.1. Method 1: Generalized Linear Regression
To determine the mappings, one finds the functions:
a) fτ (b∗) ≈ τˆ ∗ and b) fu (b∗) ≈ 3ˆ
−1
∗ where us is a row
vector containing non-zero elements of the upper (or lower)
triangular part of 3ˆ
−1
s . Since 3ˆ
−1
is a covariance matrix
(hence symmetric), knowledge of the lower/upper half of the
off-diagonal elements plus the diagonal elements is sufficient to
fully recreate the matrix.
The mappings are learnt from the training data, in which
the posterior distributions of τˆ s and 3ˆ
−1
s are already available
through Equation (A5) in Supplementary Material. Linear
regression models of the form Y = PˆB were used to model the
two mappings, where the matrix B has rows of bs vectors—one
for each subject in the training set—and similarly Y is composed
of rows of a) τ s for determining fτ or b) us for determining
fu. The least squares solutions for the models are given by the
Moore-Penrose pseudo-inverse,
Qˆ =
(
B⊺B
)−1
B⊺Y. (6)
For prediction, fτ and fu can both be formulated as f(b∗) = b∗Qˆ.
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The posterior estimates for the hyperparameters for a new
patient are taken as the averaged values of αˆs and βˆs across all
subjects in the training set, resulting in αˆ∗ = 5.5 and βˆ∗ = 1.7.
3.3.2. Method 2: Gaussian Kernel Weighted
Averaging
An alternative method is to find τˆ ∗ and 3ˆ
−1
∗ using a weighted
average of τˆ s′ and 3ˆ
−1
s′ , with s
′ ∈ S∗ being a subset of subjects
in the existing training pool whose baseline variables (bs′ ) were
“similar” to those of the new patient (b∗). Highly similar subjects
will have a higher influence on the value of τˆ ∗ and 3ˆ
−1
∗ . The
“(dis)similarity” ds is measured using the pairwise euclidean
distance between bs and b∗, such that
ds = (b∗ − bs) (b∗ − bs)
⊺ . (7)
This is then sorted and the 17.5% of subjects in S∗ with the
smallest “dissimilarity” values are kept; this percentage value was
chosen as it resulted in the lowest validation error. The weighting
ws was taken as the normalized Gaussian kernel
ws =
exp
(
−λ · ds
)
∑
∀s′∈ S∗
exp
(
−λ · ds′
) (8)
where the parameter value λ = 1.15 was chosen as it again
resulted in the lowest validation error. Using Equations (7) and
(8), one can estimate τˆ ∗ and 3ˆ
−1
∗ as
τˆ ∗ =
∑
∀s∈S∗
wsτ s, (9a)
3ˆ
−1
∗ =
∑
∀s∈S∗
ws3
−1
s , (9b)
and similarly the estimates of the hyperparameters are calculated
using
αˆ∗ =
∑
∀s∈S∗
wsαs, (9c)
βˆ∗ =
∑
∀s∈S∗
wsβs. (9d)
3.4. Prediction Using the Posterior
Predictive Distribution
When a new subject visits the clinician, their b∗ vector may
be measured and used to approximate τˆ ∗, 3ˆ
−1
∗ , αˆ∗ and βˆ∗
using either of the methods in the previous subsections. Given
a hypothetical medication input x∗, the treatment response for
the new subject can then be predicted through the posterior
predictive distribution
Pr
(
y∗
)
= tν
(
x∗τˆ ∗,
βˆ∗
αˆ∗
(
I+ x∗3ˆ∗x
⊺
∗
))
(10)
where the number of degrees of freedom for the Student’s
t-distribution is given by ν = 2αˆ∗.
Equation (10) may be used to predict the treatment response
for this new patient over their course of the treatment
directly without learning; that is to treat each appointment
as independent and the parameters are not updated. On the
other hand, it is possible to perform incremental Bayesian
learning over the course of treatment, by using Equation (A5)
in Supplementary Material to update the parameters given
the treatment outcome measured for each new visit and the
associated inputs. Through incremental learning, the model
corrects for discrepancies between the true profile and the virtual
patient profile of the new patient. As such, one would expect
the prediction to improve as data from more visits to the
clinic become available. The implementation of these methods is
discussed in more detail in Section 4.4.
At some point, the profile of the new patient in terms of the
treatment outcome, inputs, and baseline characteristics can be
added to the pool of existing patient profiles (training set) to
improve the model’s generalizability for future patients.
3.5. Training and Validation
As discussed in Section 3.1, 157 patients with longitudinal
data were randomized and 10-fold cross-validation partitions
were constructed resulting in 10-folds of training-validation data
partitions.
First, for each fold, the framework detailed in Section 3.2 was
followed and Bayesian linear regression was performed to fit
patient-specific parameters to each patient in the training dataset.
Second, either of the methods specified in Section 3.3 was used in
order to construct virtual patient profiles for each patient in the
validation set, using the patient-specific parameters. Finally, the
procedure outlined in Section 3.4 was followed in order to obtain
a prediction for patients in the validation set; effectively treating
each patient as new.
3.6. Dichotomous Remission Prediction
Although the model was initially formulated to predict
a continuous scale of symptom scores, one can explore
dichotomizing the outcome into patients who have shown
reduced symptoms and those who have not. The justification is
that clinicians and doctors are less likely to be interested in a
predicted SNAP-IV score or symptom severity scale as opposed
to a simple “yes/no” answer as to whether the patient will be
in remission for a given medication. A simple way to adapt the
current model to do this is to apply a threshold to the continuous
symptom score prediction, below which the patient is predicted
to be in remission.
Some of the literature loosely defines remission in ADHD as
having a large majority of SNAP-IV responses rated in category 0
(not at all) or 1 (a little) (Hechtman, 2005; Chou et al., 2012).
Therefore in this paper, the thresholds were chosen such that
the approximate continuous symptom score corresponds to the
raw responses from the 18-item SNAP-IV questionnaire all lying
in category 1. The resulting symptom score thresholds are only
slightly different for inattentiveness and hyperactivity (−0.97 vs.
−0.92, see Section 2.3).
Frontiers in Physiology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 199
Wong et al. Personalized Response Prediction for ADHD
Using these thresholds, it was found that the proportion of
visits when measurements were taken indicates that remission
was relatively rare, 160 out of a total of 1, 147 (13.95%) for
the inattentiveness score and 139 (12.1%) for the hyperactivity
score. This is expected, as forced titration initially starts with a
low medication dosage and one would not expect an effective
reduction in symptom ratings to remission levels before the
dosage was ramped up in later appointments; in addition,
because of medical persistence issues patients can drop out before
the clinicians are able to find an effective dose.
Note that all the methods in this paper were first used
to predict the continuous symptom scores by regressing the
baseline variables, medication prescribed to the treatment
response at following appointments. Dichotomized remission
prediction only occurs at a later stage. Right censoring (where
patients prematurely drop out of dose optimization stage
without achieving remission) is therefore not an issue; repression
methods can utilize the remaining appointment information to
model treatment response regardless of whether remission was
achieved or not.
4. PERFORMANCE METRICS
To facilitate a comparison between the performance of the
different approaches, several performance metrics were used.
For the regression tasks, one is interested in the deviation in
the predicted symptom scores against the true symptom scores;
whereas for the remission classification tasks, one is interested in
the performance of the classifiers with regard to the probabilities
or ratios of true positive, false positive, true negative and false
negative cases.
4.1. Regression Task
The root mean squared (rms) error measure is defined as the
square of the averaged squared error across the 10-folds, across
subjects and across all appointments for each individual, i.e.,
√√√√rms = 1
10|S|
10∑
k=1
∑
∀s∈S
As∑
a=1
A−1s
∣∣ys − yˆs∣∣2 (11)
where S is the set of all subjects considered (e.g., those in the
validation set), |S| denotes the number of subjects in S; ys, yˆs, and
As are, respectively, the true outcome symptom score, the fitted
or predicted outcome symptom score, and the total number of
appointments for the individual subject s.
4.2. Classification Task
4.2.1. Sensitivity and Specificity
The sensitivity (SEN, also known as the true positive rate
or recall) is defined as NTP/NP where NTP is the number
of true positives—appointments where measurements indicated
remission and were correctly predicted as such; and NP is the
actual number of positive cases, i.e., the number of appointments
where the corresponding subjects were indeed in remission. This
is reported in addition to the specificity (SPC, also known as
the true negative rate or fall-out), defined as NTN/NN, where
NTN is the number of true negatives—those not in remission
and correctly predicted as such; and NN is the actual number of
negative cases (Fletcher and Fletcher, 2005). Note that if one lets
NFP and NFN be the number of false positives and false negatives
respectively, then NP = NTP + NFN and NN = NTN + NFP
(Fletcher and Fletcher, 2005).
Sensitivity characterizes the ability of a classifier to rule out
false negative predictions (type-II errors) given that a condition
is true. On the other hand, specificity measures the ability of
a classifier to rule out false positive predictions (type-I errors)
given that a condition is false. In this exercise, the sensitivity
measure is more important; due to the rarity of remission, and
the goal is to try to predict what level of medication is required
to achieve remission, the ability of a classifier to recall remission
cases (ruling out type-II errors) is more important than ruling out
type-I errors.
4.2.2. PPV and NPV
The positive predictive value (PPV, also known as the precision)
is the proportion of true positives in the predicted positive cases
and is the probability of remission given a positive prediction by
the algorithm. As such, the PPV is a measure of the “quality” of
a given positive prediction. PPV is given by NTP/(NTP + NFP).
Conversely, the negative predictive value (NPV) is the proportion
of true negatives in the predicted negative cases, and is the
probability of non-remission given a negative prediction. NPV
is given by NTN/(NTN + NFN) (Fletcher and Fletcher, 2005).
By the argument outlined above, the PPV is more important
for this exercise than the NPV.
4.2.3. Balanced Accuracy
The overall accuracy of a dichotomous predictor is defined by
Accuracy = (NTP + NTN)/N,
where N = 1, 147 is the total number of appointments across all
subjects.
However, the overall accuracy measure is known to be
problematic when the prevalence of success/failure is low (Alberg
et al., 2004), i.e., the data are imbalanced (see also the end of
Section 3.6). Due to this, some of the literature uses the balance
accuracy (BAC) measure, defined as the average of sensitivity and
specificity (Brodersen et al., 2010). This is the accuracy measure
used throughout this paper. Note that, numerically, the BAC is
closely related to the Youden’s J-statistic (Youden, 1950), also
known as “informedness” or “DeltaP′” (Powers, 2011), since it
is equal to sensitivity plus specificity minus one.
4.2.4. ROC and AUC
The receiver operating characteristic (ROC) curve is commonly
used in the medical and the machine learning community to
evaluate the performance of binary classifiers Fawcett (2006).
It plots the true positive rate (sensitivity) against the false
positive rate (one minus specificity) for a given classifier. A curve
is obtained when its classification performance can be tuned
through setting a threshold or changing a parameter, trading
off the true positive rate against the false positive rate. Binary
classifiers that can achieve good compromise between sensitivity
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and specificity have a large area-under-the-curve (AUC), and this
single metric may be used to compare the performance between
the different classifiers Bradley (1997).
4.3. Trading Off Sensitivity and Specificity
From Section 3.6, the proportion of appointments without
remission is (100 − 13.95)% = 86.05%. Therefore, given this
statistic, one would expect that a null model guessing the result
randomly would have a sensitivity of 13.95% and a specificity of
86.05%. Simply using point estimates of the continuous symptom
score from the learning in the model space approach and
thresholding them to give dichotomous predictions of remission
results in classifiers with low sensitivity values between 22 and
28% and high specificity values of 94–97%. Due to the low
number of remission cases compared to the non-remission cases,
the classification is biased against predicting the remission cases,
leading to low sensitivity (but high specificity). A classifier can
be tuned to improve its sensitivity performance by trading off
specificity to a certain degree. A good compromise would be
maximizing both sensitivity and specificity equally, which is
in essence maximizing the BAC or the Youden’s J-statistic in
Section 4.2.3.
The thresholds for remission are defined by the SNAP-IV
symptom factor scores as in Section 2.3, and this defines the
ground truth of whether a patient is in remission or not.
However, one can take advantage of the fact that the predicted
continuous symptom scores from the learning in the model space
approach form full posterior distributions with uncertainties
associated, and the levels of uncertainty are known (e.g., see the
error bars in Figures 5, 6). One may define a critical value as
the lower bound of the prediction, above which the probability
of the prediction being correct is x%. Instead of the remission
thresholds comparing against the point estimates, they may be
compared against the point estimates minus a critical value. The
larger the critical value, the higher the prediction score has to
be in order to be classified as not in remission. This in effect is
equivalent to raising the threshold, classifying more and more
cases into remission, which increases the sensitivity and lowers
the specificity. The range of “thresholds” or classifier parameter
settings that makes this trade-off can be used to generate a
ROC plot (Section 4.2.4). A similar trade-off can be made with
classical machine learning algorithms and will be discussed in
Section5.
The training data are used to find an optimal classifier setting
in order to achieve the highest BAC, and the same classifier
setting is then used to classify the validation data. This ensures
that the validation data are not used to minimize the validation
error.
4.4. Benchmarking and Implementation
The Bayesian learning in the model space approach relies on
prior knowledge (Section 3.2.1) and virtual patient profiles in the
model space (Section 3.3), as well as iterative learning (Bayesian
update) in order to function. To assess whether these components
contribute to the prediction capability of the model, several
implementation strategies are investigated, namely:
1. Appointment-independent prediction (AI):Treating each
appointment as independent (as the first appointment) and
giving a prediction only using the virtual patient profile;
2. Incremental Bayesian linear regression (BR): The first
prediction is performed in exactly the same manner
as the appointment-independent case. Then, Bayesian
linear regression using elicited priors (see Section 3.2.1)
is applied progressively. That is, the effect/outcome of
medication prescribed in appointment 1, then observed
at appointment 2, is used in the regression model. Then,
at appointment 3, outcomes from appointments 1 and
2 are used. Similarly, at appointment 4, outcomes from
appointments 1, 2 and 3 are used, and so on. This means
that except for the first prediction, the incremental Bayesian
linear regression learns from scratch the patient-specific
parameters (at each appointment) using the elicited priors.
This essentially disregards any information already learnt
from the current training set (the virtual patient profiles),
treats the validation set as a new “training” set, and performs
basic Bayesian linear regression fitting. However, instead
of all appointment outcomes being available for each new
patient, as is the case during the training phase, one
simulates the fact that information is progressively collected
during the course of treatment for new patients. Since the
virtual patient profiles are not utilized, this serves as a
benchmark reference to evaluate the effectiveness of the
constructed virtual patient profiles when compared with the
next case; this represents a method that can be implemented
even when no training data exist.
3. Incremental Bayesian learning/update (BU): The first
appointment is predicted as for the previous two cases,
but then when the true value is observed (in appointment
2), it is fed-back into the Bayesian learning model, i.e.,
Equation (A5) in Supplementary Material. This updated
model is then used to generate a prediction. This progressive
updating continues up to the most recent appointment. The
crucial difference between this method and the BR method
is that, here, the priors used were derived from the virtual
patient profiles, as opposed to the elicited priors used in the
BRmethod. When compared to the BR case, this highlights
whether the model space offers any utility in aiding the
prediction of treatment response.
The Bayesian approach was implemented ad hoc in
MATLAB software with custom routines. The performance
of the prediction was compared across the three different
implementations above, using the validation data.
5. COMPARISON WITH CONVENTIONAL
METHODS
To provide context to the results achieved using the learning
in the model space approach, the performance of conventional
linear regression methods and machine learning methods was
also investigated.
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FIGURE 5 | Examples of Bayesian linear regression on continuous inattentiveness (INA) and hyperactivity (HYP) symptom scores with the Bayesian
linear regression training dataset (BRR). (A) Subject #11, (B) Subject #74.
FIGURE 6 | Examples of continuous hyperactivity symptom score prediction with the validation set. (A) Subject #6. (B) Subject #148.
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5.1. Mixed Effects Models
Linear mixed effects models (MEM) are widely used in many
fields; for instance, biology (Rico et al., 2007), ecology (Stevens
et al., 2007), linguistics (Nooteboom and Quené, 2008) and social
sciences (Kliegl et al., 2009). They extend upon classical linear
regression techniques to support data that have some form of
grouping. For example, in this paper, each patient had one or
more clinical appointments, and the data from each subject form
a group. For each patient s with a number of appointments (from
1 to As), the severity symptom score vector ys (as in Equation 2)
is, for simplicity, assumed to have a linear relationship with the
baseline and treatment effect via the following formulation:
ys = qs + b0 + Xˆsωs + ǫ, (12)
where Xˆs is similar in structure to X defined in Equation (4)
but without the last column of ones; ωs ∈ RP×1 is the subject-
specific parameter vector for the fixed effects, qs ∼ N(0, σ
2
q )
is the random effect affecting only the intercept b0, and ǫ ∼
N(0, σ 2ǫ,s) ∈ RAs×1 is an error term assumed to have a normal
distribution. Observe that in this model, the scalar intercept b0
is a fixed component for all of the patients in the population and
the random effect as is a subject-specific scalar and is not grouped
under any other parameters.
A linear mixed effects model was constructed within the
R software (R Core Team, 2013), using the package “lme4”
(Bates et al., 2015). Severity score predictions were produced
by performing out-of-sample forecasts, i.e., on the validation
data for each of the folds, using the “predict” function in the
R software. To generate a prediction, the random effects are
assumed to be zero and the population intercept was used. The
continuous symptom score regression results for the MEM are
prefixed MER.
For a dichotomized clinical remission classification, the
symptom score thresholds 0.92 and 0.97 from Section 2.3
for hyperactivity and inattentiveness were used to generate
the ground truths. Following the rationale in Section 4.3, the
symptom scores predicted by the MEM are given thresholds
at different levels to produce a set of classifiers trading off
sensitivity against specificity. These threshold-adjusted classifiers
are labeled taMEC. The best (in terms of Youden’s statistic)
threshold settings found using the training data were used for the
validation data; the thresholds were 0.05 and -0.20, respectively,
for the inattentiveness and hyperactivity symptom scores. In
addition, the “melogit” function in the Stata software (StataCorp,
2015) was used to directly estimate a mixed effects logistic
regression model—a MEM with a logistic link function that
predicts the probability of the binary remission outcome. In this
case, the threshold procedure was applied to the probabilities
rather than the raw symptom scores. The resulting classifier is
labeled lrMEC.
5.2. Support Vector Machines and
Gaussian Processes
In addition to MEM, machine learning classification approaches
using support vector machines (SVM) and Gaussian processes
(GP) were benchmarked. Both the SVM and GP learning
methods are kernel machines and were implemented using linear
(dot product kernel: k(xi, xj) = (xi.xj)) and nonlinear kernels
(the Gaussian kernel: k(xi, xj) = exp
[
−γ(‖xi − xj‖)
2
]
). Readers
are invited to refer to Burges (1998) for a detailed description of
support vector machines and to Rasmussen and Nickisch (2010)
for a detailed description of GP learning. Compared to MEM
and the learning in the model space approach, the SVM and
GP are non-parametric methods—there are no subject specific
parameters to identify; the models map the subject-specific
inputs, such as baseline characteristics and the medication
dosage, to the output symptom scores.
For the SVM, nested cross-validation was employed to
optimize the parameters in the model. A broad log range
spanning [10−3 : 102] was arbitrarily chosen as the search
range for the regularization parameter C. Similarly, the gamma
parameter of the Gaussian kernel was optimized in the log range
spanning [10−4 : 101]. For the GP, the model parameters were
optimized using conjugate gradient descent, avoiding the need
for nested cross-validation. SVM and GP learning approaches
were employed as regression models (support vector regression
SVR and Gaussian process regression GPR) for the linear and
nonlinear kernels to predict the clinical scores. Dichotomous
remission predictions were obtained by thresholding the distance
from the hyperplane for the SVM, and for thresholding the
probabilistic predictions of class membership for GP. These
binary classifiers are respectively labeled as SVC and GPC.
From Section 3.6, the number of remission cases outweighed
non-remission cases by a ratio of roughly 1:7. For a classification
task, this imbalance of data is problematic for many classification
algorithms (He and Garcia, 2009). To help alleviate this, a
downsampling approach was implemented for both linear and
nonlinear kernels of the SVM and GP classifiers dsSVC and
dsGPC. During the training phase, the non-responder class
was downsampled randomly to match the number of training
instances in the remission class. By repeating this downsampling
procedure, an ensemble of 1,000 classifiers was trained. A
classification prediction was generated by majority voting of
the ensemble. Additionally, for the SVMs, an alternative is to
learn the regularization parameters C on a per-class basis. The
rationale is that a higher penalty for errors can be placed on the
more abundant class (Osuna et al., 1997); this method is referred
to as the weighted SVM (rwSVC). The per-class C parameters
C+ and C− were optimized using the ranges
[
10−3 : 101
]
and
[
10−2 : 102
]
, respectively. Finally, for the Gaussian process
classifier, it is possible to calibrate the probabilistic predictions
in order to help account for imbalanced data (Bishop,
2006); this approach is referred to as a re-calibrated GP
(rcGPC).
UsingMATLAB software, the SVMwas implemented using the
libsvm toolbox (Chang and Lin, 2011), the Gaussian process
learning was implemented using the GPML toolbox (Rasmussen
and Nickisch, 2010).
6. RESULTS AND DISCUSSIONS
6.1. Continuous Symptom Score Prediction
The rms errors across all models are reported in Table 1.
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TABLE 1 | Rms errors for predicting symptom scores for inattentiveness (INA) and hyperactivity (HYP) using the (A) learning in model space and (B)
conventional approaches.
(1A) Learning in model space
Inattentiveness Hyperactivity
Method 1 Method 2 Method 1 Method 2
AIR* 0.98 0.84 0.97 0.85
BRR† 0.82 0.82 0.84 0.84
BUR‡ 0.99 0.73 1.01 0.75
*AIR: appointment-independent Bayesian linear prediction.
†BRR: retrospective Bayesian linear regression.
‡BUR: incremental Bayesian learning/update linear regression.
(1B) Conventional approaches
Kernel Inattentiveness Hyperactivity
Linear Nonlinear Linear Non-linear
SVR* 0.73 0.74 0.76 0.81
GPR† 0.72 0.77 0.76 0.84
MER‡ 0.82 0.83
*SVR: support vector machine regression.
†GPR: Gaussian processes regression.
‡MER: mixed effects regression.
6.1.1. Learning in the Model Space Approach
Looking at the learning in the model space approach, one can
observe that the virtual patient profile construction method,
labeled Method 2, resulted in lower errors overall compared
to Method 1. In Method 1, the mappings were learnt using
simple linear regression from baseline variables to the parameter
space. In addition to this simple linear regression, low degree
polynomial (quadratic to quartic) basis functions were tried;
whilst degrees up to a cubic resulted in a slightly lower training
error, there was worse generalizability (i.e., higher validation
error). For Method 2, the incremental Bayesian learning (BUR)
approach performed the best overall; its performance advantage
over the appointment-independent prediction (AIR) approach
is expected given that it allows the model to adapt to a
new patient as the treatment continues. The performance
advantage over the retrospective Bayesian linear regression
(BRR) approach can be attributed to the fact that the virtual
patient profile (Section 3.3) had utilized the prior whilst
the Bayesian linear regression only uses the elicited prior
(see Section 3.2.1). This supports the fact that the training
population was able to add valuable information to the prediction
task.
We recall that the BUR constructs virtual patient profiles while
the BRR only uses the prior knowledge. It is interesting to note
that the BRR outperforms the BUR using Method 1, suggesting
that Method 1 was not an effective method for incorporating
information from existing patient models.
Figure 7 shows the rms values averaged across all subjects
during the validation phase and sorted by the clinical
appointment (visit) number. Data above 15 visits are not
shown as only a single patient had more than 15 visits. There
is a slight downward trend visible with the BUR; suggesting
that incremental Bayesian learning approach is able to reduce
the prediction error as more data are known about a new
patient through repeated appointments. The BRR also shows a
downward trend, but the error is slightly higher than the BUR.
This is because the BRR starts with only the elicited prior and
performs learning (fitting) when more data are available, unlike
the BUR which starts off with information from the training set
in the form of a constructed/estimated virtual patient profile.
Figure 5 illustrates some examples of Bayesian linear
regression performed during the training phase and their
associated fitting rms errors. It can be seen that Bayesian
linear regression fits similarly well for both the inattentiveness
and hyperactivity symptom scores. Switching to a new type
of medicine is usually associated with larger uncertainty
(error bars). Looking at subject #74 (Figure 5B) in particular,
it can be seen that, despite having the same input dosage
from appointments 6–8, there were variations in the severity
of the ADHD symptoms. It is not possible to know the
exact reason for the variation for this subject during this
particular period, without further information—perhaps
this was due to adherence issues (the patient not taking
their medication as prescribed), physiological factors,
measurement “noise,” or perhaps something else entirely.
By design, Bayesian linear regression can only fit the same
outcome given the same input. This does highlight the fact
that the current model may not have enough information
in the form of covariates to account for some of these
factors.
A subset of results for the validation phase is plotted in
Figure 6. For brevity, only prediction outcomes for hyperactivity
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FIGURE 7 | Rms prediction (validation) error averaged across all
subjects vs. appointment number.
symptom scores are shown and retrospective Bayesian linear
regression results (BRR) are omitted. The lack of solid lines
connecting the predictions in the topmost subplot serves as a
reminder that the model does not incorporate temporal aspects
for the case of appointment-independent (AIR) prediction,
which treats each appointment as the first (new) appointment
for a new patient. This is also why the 95% confidence intervals
for AIR are larger (more uncertain) than those for the BUR.
Also note that, by design, the prediction results for the first
appointment are identical for both approaches.
The figures illustrate that, during prognosis, incremental
learning does not always improve the prediction error compared
to simply predicting at every appointment without updating
the model using new information. However, based on the
rms errors in Table 1A, one expects incremental learning to
perform better overall across subjects, especially for subjects
with a prediction offset, such as over- or under-estimates.
This is illustrated by the results for subject #148 given
in Figure 6B, where the virtual patient profile for this
patient consistently underestimates the actual hyperactivity
score. Here, the incremental Bayesian learning was able to
adapt the parameter ω and shifted the prediction upwards,
resulting in lower prediction errors over the subsequent
appointments.
6.1.2. Conventional Machine Learning Approaches
Looking at the results in Table 1B, the conventional approaches
yield similar performance, with linear SVR and GPR methods
performing better than their nonlinear counterparts. The mixed
effects model has slightly worse results. Errors of linear SCR and
linear GPR are similar to each other, and to those for the learning
in the model space approach BUR with Method 2. We conclude
that for the task of predicting continuous symptom scores with
the dataset investigated, the learning in themodel space approach
performs comparably with conventional approaches.
6.2. Dichotomous Remission Prediction
6.2.1. Learning in the Model Space Approach
For the learning in the model space approach, the ROC curves
for the dichotomous predictor are plotted in Figure 8 for both
of the virtual patient profile (Section 3.3) construction methods.
As the results for inattentiveness and hyperactivity scores were
similar, only the ROC curves for inattentiveness are shown.
The AUC values are given in the legend. The crosses on the
lines mark the resulting classifier performance if one uses point
estimates for the continuous symptom score from the model
and simply applies the clinical remission thresholds. The squares
mark the classifiers that have critical values based on maximizing
the Youden’s J-statistic (or the BAC, see Section 4.2.3) for the
training set—this is equivalent to the sensitivity and specificity
measures being maximized equally as a function of the critical
values. Lastly, the circles mark the best classifier for the
validation set in terms of the Youden’s J-statistic. The closer
the squares are to the circles, the better optimized the classifier
is assuming no knowledge of the validation dataset. Those
optimized classifiers marked by squares in the graph are used
to generate various binary classifier performance metrics (see
Section 4.2) in Table 2.
Looking at Table 2. The confusion matrices (CFM) show the
number of true positives and false negatives in the first column,
and false positives and true negatives in the second column.
These may be used to calculate any classification performance
metrics not included in this paper, such as the F-measure.
Similar to the continuous symptom prediction task, the BRC
outperforms the AIC showing that posterior information is
utilized effectively. As in the continuous task, the virtual patient
profile construction method labeled Method 2 is better overall
than Method 1, but the difference is much smaller in the
classification task and the advantage is not universal across all
metrics, especially for the AIC. Note that the virtual patient
profile construction method has little effect on the BRC as it does
not use it. The BRC achieves higher sensitivity values but a lower
PPV compared to the BUC, meaning that the BRC is better at
recalling remission cases, but the remission predictions by the
BUC are more reliable. The SPC achieved by the BUC is notably
higher, being better at ruling out false positives.
6.2.2. Conventional Machine Learning Approaches
Table 3 shows the binary classifier performance metrics for
the conventional machine learning approaches. Apart from the
AUC, all of the other metrics in the table were derived from
classifier settings (set-points) that had optimized the balanced
accuracy (BAC) during the training stage. Apart from rcGPC,
the BAC values across the different approaches are similar. The
MEC classifiers perform well compared with GPC and SVC,
with consistently high AUC values for both inattentiveness and
hyperactivity. However, the set-points of the MEC classifiers
achieve lower sensitivity (but higher specificity) than the SVC. As
mentioned in Section 4.2, a higher sensitivity is more important
for this exercise. PPV is the other measure of interest; the
lrMEC, in particular, achieved the highest PPV amongst all the
conventional approaches—partially helped by its low sensitivity.
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FIGURE 8 | Receiver operator characteristic (ROC) plots of inattentiveness prediction using virtual patient profile constructed by Methods 1 and 2
(A,B) in the learning in model space approach; crosses: no critical value adjustment (based on point estimates); squares: best performing critical values on training
set; circles: best performing critical values on the validation set; AUC: Area under the ROC curve AIC: appointment-independent classifier; BRC: retrospective
Bayesian linear regression classifier; BUC: incremental Bayesian learning/update classifier.
The ROC plot for the MEC is shown in Figure 9. The lrMEC
variant fitted the training set better but both the lrMEC and
the taMEC achieve similar validation performance. Tracing the
ROC values, the lrMEC seems more suitable for high specificity
settings while taMEC appears to be more suitable for high
sensitivity classification.
For the machine learning approaches GPC and SVC,
linear models work better. This was similarly observed in
the continuous symptom score prediction task. Comparing
methods in tackling data imbalance, the weighted SVM classifier
rwSVCmethod performed better than the downsampled dsSVC
method, while the downsampled Gaussian process classifier
dsGPC method performed better than the re-calibrated rcGPC.
Looking at both the BAC and AUC metrics, rwSVC and dsGPC
perform similarly, with the former slightly better at classifying
remission of hyperactivity, whereas the latter is slightly better for
inattentiveness.
Overall for the conventional methods, the rwSVC achieves
the best compromise between SEN and PPV, meaning that
it can identify remission cases more readily and at the same
time the remission predictions are more reliable. Comparing
Tables 2, 3 it can be seen that the learning in the model
space approach is superior overall. With respect to the BAC
and AUC measures, the best performing BUC approach has an
advantage of about 6–7%. This is interesting given the similar
performance in the continuous symptom score prediction task
amongst all approaches. The rms error measure in the symptom
score prediction task was based on point estimate calculations,
and thus used no information on the shape of the posterior
distribution. The posterior predictive distribution (Section 3.4)
for the BUC has a Student’s t-distribution specific to each patient.
The distributions were used to construct a probabilistic threshold
in trading off specificity and specificity. This subject-specific
nonlinear thresholding procedure may have contributed to its
performance advantage over other approaches.
6.2.3. Comparison with Literature
As far as the authors are aware, Kim et al. (2015) is the
only published literature on treatment response prediction of
ADHD patients using machine learning techniques. Their best
attempt achieved an AUC value of 0.84 and 86.4% classification
accuracy (that is, the percentage of correct predictions, different
from the BAC measure used in this paper) using a wide
range of information types including demographical, clinical,
genetic, environmental, neuropsychological and neuroimaging
measures. In comparison, this paper includes only the more
readily obtainable demographical and clinical information and
is able to achieve best-case AUCs of 0.82–0.84. Restricting to
demographical and clinical information, the highest performing
method using SVMs in Kim et al. (2015) had an AUC of
0.69. Granted, the comparison is imprecise because the quality,
quantity and sources of demographical and clinical information
are different between this paper and Kim et al. (2015). Judging
from the AUC values achieved by SVMs in this paper of about
0.71 (see Table 3), the results appears to be very close to those in
Kim et al. (2015). Due to this similarity, the previous comparisons
should be valid.
7. CLINICAL UTILITY AND FURTHER
WORK
The proposed learning in the model space approach is capable of
predicting, for an individual, the minimum dosage of a particular
medication required to have a user-defined chance of achieving
symptomatic remission. It is highly flexible and potentially can
be extended to any disease or disorder where medication is used
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TABLE 2 | Sensitivity, specificity, accuracy, and AUC of the remission classifier with critical values adjusted with respect to uncertainties in the predicted
symptom scores.
Inattentiveness Hyperactivity
Method 1 Method 2 Method 1 Method 2
C
F
M
a AIC
* 93 327
67 660
141 501
19 486
82 314
57 694
121 448
18 560
BRC†
140 482
20 505
140 483
20 504
125 480
14 528
125 483
14 525
BUC‡
117 338
43 649
123 280
37 707
97 307
42 701
109 253
30 755
S
E
N
b
AIC 58.1% 88.1% 59.0% 87.1%
BRC 87.5% 87.5% 89.9% 89.9%
BUC 73.1% 76.9% 69.8% 78.4%
S
P
C
c AIC 66.9% 49.2% 68.9% 55.6%
BRC 51.2% 51.1% 52.4% 52.1%
BUC 65.8% 71.6% 69.5% 74.9%
B
A
C
d AIC 62.5% 68.7% 63.9% 71.3%
BRC 69.3% 69.3% 71.2% 71.0%
BUC 69.4% 74.3% 69.7% 76.7%
P
P
V
e
AIC 22.1% 22.0% 20.7% 21.3%
BRC 22.5% 22.5% 20.7% 20.6%
BUC 25.7% 30.5% 24.0% 30.1%
N
P
V
f AIC 90.8% 96.2% 92.4% 96.9%
BRC 96.2% 96.2% 97.4% 97.4%
BUC 93.8% 95.0% 94.4% 96.2%
A
U
C
g AIC 69.0% 72.0% 68.0% 73.8%
BRC 81.2% 80.9% 83.6% 83.3%
BUC 77.1% 82.3% 76.7% 84.4%
aCFM: confusion matrix.
bSEN: sensitivity.
cSPC: specificity.
dBAC: balanced accuracy.
ePPV: positive predictive value.
fNPV: negative predictive value.
gAUC: area under ROC curve.
*AIC: appointment-independent classifier.
†BRC: retrospective Bayesian linear regression classifier.
‡BUC: incremental Bayesian learning/update classifier.
Shaded values represent best performance amongst the compared methods.
in the course of treatment, speeding up and reducing the cost
of the dose optimization/forced titration process, and potentially
improving the quality of life for patients by ending the treatment
sooner.
The current model, however, does not take into account
adverse drug reactions (ADRs), minimization of which is another
goal of a dose optimization titration process. To improve clinical
utility, it is essential that ADRs are modeled. While data on this
are available from the clinical notes accompaning the ADDUCE
trial, a different modeling approach is required to incorporate
the many different types of ADRs, with prevalence ranging from
infrequent to very rare.
While the proposed approach achieves excellent performance
in terms of treatment response classification, there is room for
improvement. One obvious way to achieve this is to incorporate
more data, especially covariates that are functions of time.
In this exercise for example, the body mass index and age
variables measured at baseline (first appointment) of the patients
contribute to the latent factors, which in turn form the baseline
variables. As such, they do not vary over time. It may be worth
investigating whether the addition of temporal covariates, such
as blood pressure, would improve the model.
Another venue for potential improvement is to extend the
linear model to a nonlinear model—there is no guarantee that all
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TABLE 3 | Sensitivity, specificity, accuracy, and AUC of the remission classifier with critical values adjusted with respect to uncertainties in the predicted
symptom scores.
Inattentiveness Hyperactivity
Linear Non-linear Linear Non-linear
S
e
n
si
tiv
ity
dsSVCa 70.0% 70.6% 67.6% 66.9%
dsGPCb 68.1% 67.5% 67.6% 66.9%
rwSVCc 76.9% 33.8% 76.9% 69.1%
rcGPCd 43.1% 43.2% 71.3% 48.2%
taMECe 60.0% 58.9%
lrMECf 53.1% 56.0%
S
p
e
c
ifi
c
ity
dsSVC 61.9% 62.3% 67.8% 66.6%
dsGPC 67.9% 69.1% 67.8% 71.3%
rwSVC 55.9% 77.6% 62.1% 62.1%
rcGPC 59.0% 18.4% 50.7% 50.6%
taMEC 73.3% 73.8%
lrMEC 81.4% 81.4%
B
a
la
n
c
e
d
a
c
c
u
ra
c
y dsSVC 66.0% 66.5% 67.7% 66.7%
dsGPC 68.0% 68.3% 67.7% 69.1%
rwSVC 66.4% 55.7% 69.5% 65.6%
rcGPC 51.1% 44.8% 46.9% 49.4%
taMEC 66.6% 66.4%
lrMEC 67.2% 70.6%
P
o
si
tiv
e
p
re
d
ic
tiv
e
va
lu
e
dsSVC 23.0% 23.3% 22.4% 21.6%
dsGPC 25.6% 26.2% 22.4% 24.3%
rwSVC 22.0% 19.6% 21.9% 20.1%
rcGPC 15.6% 12.4% 10.8% 11.9%
taMEC 26.7% 23.7%
lrMEC 31.6% 29.0%
N
e
g
a
tiv
e
p
re
d
ic
tiv
e
va
lu
e
dsSVC 92.7% 92.9% 93.8% 93.9%
dsGPC 92.9% 92.9% 93.8% 93.4%
rwSVC 93.7% 87.8% 95.1% 93.6%
rcGPC 86.5% 79.8% 86.6% 87.63%
taMEC 91.8% 92.9%
lrMEC 91.5% 94.1%
A
re
a
u
n
d
e
r
R
O
C
c
u
rv
e
dsSVC 71% 69% 73% 71%
dsGPC 75% 71% 73% 70%
rwSVC 71% 60% 76% 71%
rcGPC 49% 41% 46% 48%
taMEC 74.8% 77.5%
lrMEC 75.8% 77.2%
adsSVC: down-sampled support vector machine classifier; bdsGPC: down-sampled Gaussian processes classifier; crwSVC: regularization-weighted support vector machine classifier;
drwGPC: regularization-weighted support Gaussian processes classifier; etaMEC: threshold-adjusted mixed effects classifier; flrMEC: logitic regression mixed effects classifier.
Shaded values represent best performance amongst the compared methods.
the covariates have a linear relationship with treatment response.
Identifying the level and nature of nonlinear relationships
is the first challenge. In the current Bayesian framework,
the introduction of nonlinearities increases computational
complexity for Bayesian inference, requiring the use of
techniques such as Gibbs sampling.
There are other areas of interest. For example, what is the
optimum strategy, in terms of timing and requirements, for
incorporating semi-new patient data to the model space to
improve the generalizability of the model for other new patients?
How can medical adherence/concordance be modeled? Does
gender of the patient play a role in their treatment response?
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FIGURE 9 | Receiver operator characteristic (ROC) plot of
inattentiveness prediction using mixed effects models; crosses: no
threshold adjustment (based on point estimates); squares: best
performing threshold setting on training set; circles: best performing
threshold setting on the validation set; AUC: Area under the ROC
curve; taMEC: threshold-adjusted mixed effects classifier; lrMEC:
logitic regression mixed effects classifier.
8. CONCLUSION
A learning in the model space framework has been utilized
to develop a personalized medicine approach to treatment
response prediction. First of all, factor analysis was performed
to extract latent factors from a large clinical dataset, collected
from a UK sample of 157 patients suffering from attention-deficit
hyperactivity disorder. The resulting reduced-order patient
information was then encoded in a model parameter space
resulting in a cloud of personalized models. Then, the patient-
specific model space parameters were used to train a Bayesian
linear regression model. New patients are then matched to
existing patients most similar to themselves to obtain a virtual
patient profile, which in turn forms a prior parameter set for
the Bayesian linear regression model. Through a Bayesian update
algorithm, new data are continuously integrated to improve the
prediction performance for a given patient. In addition, the
parameters of the “new” patients can be added to the model
parameter space (once sufficient data are available) to improve
the generalizability of the model for future patients.
Comparisons were made between the learning in the model
space approach with conventional data-driven machine learning
and regression approaches. In terms of the prediction of
the continuous symptom factor scores, the performance of
the learning in model space framework was on a par with
conventional approaches. However, the new approach is shown
to outperform support vector machines, Gaussian processes and
linear mixed effects classifiers in the prediction of symptomatic
remission. The effective gain in classification performance of
the new model can potentially speed up and reduce the cost
of a forced titration or dose optimization titration process,
which is normally manually performed by the clinician to
assess the effective dosage of medication. Further work includes
incorporating the prediction of adverse drug reactions, which
is also an important element in the dose optimization titration
process.
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